Beige J, Weber A, Engeli S, Offermann G, Distler A, Sharma A M
Department of Internal Medicine, Universitätsklinikum Benjamin Franklin, Free University of Berlin, Federal Republic of Germany.
Nephrol Dial Transplant. 1996 Aug;11(8):1538-41.
The angiotensinogen gene has been linked to the development of essential hypertension, and a M235T variant of this gene, associated with increased plasma levels of angiotensinogen, is more common in hypertensives than in normotensive controls in various populations. The present study was conducted to examine whether the M235T variant of the angiotensinogen gene may be a risk factor for the development of hypertension in patients undergoing renal transplantation.
DNA for genetic analysis was prospectively collected from 269 consecutive patients undergoing kidney transplantation between 1988 and 1993 and their corresponding donors. Presence of hypertension and graft survival was analysed by blinded review of all case records over a follow-up period up to 30 months. Angiotensinogen genotype was determined by a mutagenically separated allele-specific polymerase-chain-reaction technique.
While post-transplant hypertension was present in 78% of all patients, no relationship was found between either donor or recipient genotype and the presence or severity of post-transplant hypertension. Furthermore, there was no relationship between angio-tensinogen genotype and graft survival during the course of the study.
These findings do not support the hypothesis that the M235T variant of the angiotensinogen gene is a risk factor for the development of post-transplant hypertension.
血管紧张素原基因已被证实与原发性高血压的发生有关，该基因的M235T变异体与血管紧张素原血浆水平升高相关，在不同人群中，高血压患者中该变异体的出现频率高于血压正常的对照者。本研究旨在探讨血管紧张素原基因的M235T变异体是否可能是肾移植患者发生高血压的危险因素。
前瞻性收集了1988年至1993年间连续进行肾移植的269例患者及其相应供体的用于基因分析的DNA。通过对长达30个月随访期内的所有病例记录进行盲法审查，分析高血压的存在情况和移植物存活情况。采用诱变分离的等位基因特异性聚合酶链反应技术确定血管紧张素原基因型。
虽然所有患者中有78%出现移植后高血压，但未发现供体或受体基因型与移植后高血压的存在或严重程度之间存在关联。此外，在研究过程中，血管紧张素原基因型与移植物存活之间也没有关联。
这些发现不支持血管紧张素原基因的M235T变异体是移植后高血压发生的危险因素这一假说。
